Minerva Neurosciences (NERV) EBIT (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of EBIT data on file, last reported at -$16.7 million in Q1 2026.

• Quarterly EBIT fell 327.16% year-over-year to -$16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.9 million (down 46.16% YoY) and the FY2025 annual result came in at -$15.1 million, up 30.87% from the prior year.
• EBIT fell to -$16.7 million in Q1 2026, from -$5.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$2.8 million in Q3 2025 to a low of -$16.7 million in Q1 2026.
• A 5-year average of -$6.0 million and a median of -$5.2 million in 2022 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT jumped 76.28% — and 2026, when it plunged 327.16%.
• Tracing NERV's EBIT over 5 years: stood at -$5.1 million in 2022, then sank by 41.47% to -$7.2 million in 2023, then soared by 36.95% to -$4.5 million in 2024, then dropped by 10.16% to -$5.0 million in 2025, then sank by 234.66% to -$16.7 million in 2026.
• The last three EBIT figures came in at -$16.7 million (Q1 2026), -$5.0 million (Q4 2025), and -$2.8 million (Q3 2025), per Business Quant data.